Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: mNGS for patients with pulmonary infection

PROVIDER: PRJNA1140277 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR29999300.fastq.gz	Fastqsanger.gz
	SRR29999400.fastq.gz	Fastqsanger.gz
	SRR29999301.fastq.gz	Fastqsanger.gz
	SRR29999401.fastq.gz	Fastqsanger.gz
	SRR29999302.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 197

Similar Datasets

Harnessing Bronchoalveolar Lavage Metagenomics for Distinguishing Lung Cancer from Pulmonary Infectious Diseases

Project description:Recent progress in unbiased metagenomic next-generation sequencing (mNGS) allows simultaneous examination of microbial and host genetic material in a single test. Leveraging affordable bronchoalveolar lavage fluid (BALF) mNGS data, we employed machine learning to create a diagnostic approach distinguishing lung cancer from pulmonary infections, conditions prone to misdiagnosis in clinical settings. This prospective study analyzed BALF-mNGS data from lung cancer and pulmonary infection patients, delineating differences in DNA/RNA microbial composition, bacteriophage abundances, and host responses, including gene expression, transposable element levels, immune cell composition, and tumor fraction derived from copy number variation (CNV). Integrating these metrics into a host/microbe metagenomics-driven machine learning model (Model VI) demonstrated robustness, achieving an AUC of 0.87 (95% CI = 0.857-0.883), sensitivity = 73.8%, and specificity = 84.5% in the training cohort, and an AUC of 0.831 (95% CI = 0.819-0.843), sensitivity = 67.1%, and specificity = 94.4% in the validation cohort for distinguishing lung cancer from pulmonary infections. The application of a rule-in and rule-out strategy-based composite predictive model significantly enhances accuracy (ACC) in distinguishing between lung cancer and tuberculosis (ACC=0.913), fungal infection (ACC=0.955), and bacterial infection (ACC=0.836). These findings highlight the potential of cost-effective mNGS-based analysis as a valuable tool for early differentiation between lung cancer and pulmonary infections, offering significant benefits through a single comprehensive testing.

2024-01-08 | GSE252118 | GEO

Project description:mNGS results from pulmonary infection patients

| PRJNA936669 | ENA

Project description:mNGS of pulmonary infection in patients with acquired immunodeficiency syndrome

| PRJNA891782 | ENA

null

Project description:Card mNGS infection

| PRJEB72354 | ENA

Project description:mNGS in Spinal infection

| PRJNA1203379 | ENA

Clinical isolates of Staphylococcus aureus, Mycobacterium tuberculosis, Escherichia coli, etc

Project description:mNGS in Spinal infection

| PRJNA1202888 | ENA

Project description:Application of mNGS in the study of pulmonary microbiome in pneumoconiosis co-infection patients and exploration of potential biomarkers

| PRJNA985087 | ENA

Human plasma BOS iTRAQ

Project description:We compared 4 pools of plasma in the same iTRAQ proteomics experiment. The pool 1 contained plasma from twelve patients with strict BOS and with plasma sample available at onset of the clinical symptoms (named BOS), pool 2 contained plasma from sixteen patients with pulmonary infections (infection), pool 3 contained plasma from fifteen patients with chronic GVHD without pulmonary involvement (CGVHD no lung), and pool 4 contained plasma from fifteen patients after transplant with no chronic complications (at similar time point as BOS samples) (no complications).

2016-02-03 | MSV000079490 | MassIVE

Human plasma BOS iTRAQ

2016-01-11 | MSV000079451 | MassIVE

Project description:mNGS data for Cranial infection

| PRJNA1206143 | ENA